Cramer Loves These Dividend Stocks

Costco - Costco's membership model drives consistent revenue with renewal rates consistently above 90%, providing cash flow stability that supports dividend growth, making it attractive for income investors [1][5] - The company demonstrates resilience in inflationary environments through its bulk-buying model and private-label Kirkland brand, which help maintain low costs and strong margins [1] - Cramer emphasizes Costco's ability to thrive amid economic shifts, including inflation and consumer caution, as a reason to invest, especially with its global expansion and e-commerce growth [1][2] Eli Lilly - Eli Lilly is recognized for its explosive growth and reliable dividend, currently yielding about 0.69%, driven by blockbuster drugs like Mounjaro and Zepbound for weight loss and diabetes [6][10] - The company maintains a strong innovation pipeline and profitability, which supports dividend growth, positioning it well to handle patent cliffs compared to peers [7] - Recent late-stage trial results for orforglipron, an oral formulation for weight loss and diabetes management, reported significant success, indicating strong future potential for the stock [8][9] CVS Health - CVS Health is highlighted for its diversified business model, which includes retail pharmacies, health insurance through Aetna, and pharmacy benefit management, with a dividend yield of 3.36% [11][12] - The company is considered undervalued with a low price-to-earnings ratio relative to peers, despite strong cash flows that support its generous dividend [12] - Cramer points out CVS's strategic shift toward healthcare services, such as in-store clinics and telehealth, as a growth driver in a post-pandemic environment, making it a buy for investors seeking income and recovery upside [12][13]